Interventional Glaucoma

Surgeon expects more MIGS, less trabeculectomy.

Body mass index (BMI), central obesity, and the metabolic syndrome may be deciding risk factors in glaucoma.

In a poster presented at the Association for Research in Vision and Ophthalmology, authors Paul S. Kayne, PhD, Alison Obr, PhD, John H. Dodd, PhD, and Carl Spana, PhD, it was demonstrated that PL9588 reduces ocular pressure. Data provides further support for topical administration of melanocortins for ocular inflammation.

Defective calcium clearance is a characteristic feature of early damage to the retinal ganglion cells (RGC) in a mouse model of glaucoma.

Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.

Physicians are using the procedure to treat various stages of the disease.

According to the company, the outcomes reported demonstrate a favorable safety profile for its novel, noninvasive glaucoma treatment.

The device is an update on the previous iTrack canaloplasty device and features an ergonomic handpiece.

The first 2023 release of the Video Journal of Cataract, Refractive, & Glaucoma Surgery explores essential techniques for intraocular lens (IOL) removal, providing a diverse range of both routine and novel approaches within its hour-long presentation.

Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.

GAL-101 is a Phase 2/3-ready small molecule used to treat ophthalmic indications with high unmet medical need.

Ophthalmologists have discussions about driving with glaucoma patients.

Hurdles include limited space, handling thin sclera, choosing the right site.

The findings have potential clinical and public health implications and highlight the greater role of metabolic health status than obesity in IOP elevation, according to the authors.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

The researchers from Indiana University School of Medicine found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.

The procedure can provide prolonged IOP lowering in primary open-angle glaucoma with an excellent safety profile.

Automated AI tool offers offline capability and hope for patients.

The Ergo-Series of the OMNI Surgical System maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures.

Examining the anatomy and physiology may prevent ineffective stent implantation.

SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.

During a presentation at the EnVision Summit Ophthalmology 2023 at El Conquistador Resort in Puerto Rico, Elena Bitrian, MD, outlines the challenges that surgeons are confronted with surgically in pediatric eyes, including the limited working space and palpebral fissure, axial length, and avoidance of the thin sclera and shallow scleral pass.

A recent clinical study demonstrates that low intracranial pressure correlates with impaired patient visibility, especially in the nasal zone.

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.